Medullary thyroid carcinoma (MTC) is a rare disease and accounts for 3-10% of all thyroid carcinomas (Hundahl et al, 1998) . Because MTC can only be cured surgically and no effective radioor chemotherapy are available, mortality of MTC is higher than of differentiated thyroid carcinoma and accounts for up to 13.4% of all deaths related to thyroid malignancies (Marsh et al, 1995) . Serum level of basel as well as of pentagastrin-stimulated calcitonin is as established tumour marker in MTC, which is supplemented by estimation of serum levels of carcinoembryonic antigen (CEA). Hereby, early detection of metastases and local disease relapse remain to pose a major clinical problem in MTC. Searching for local relapse of distant metastases is often very difficult and includes laboratory tests as well as selective venous catheterization, ultrasound, octreotide scan, computer tomography and magnetic resonance imgaging. Therefore, molecular detection of circulating tumour cells may represent a new approach in order to improve early diagnosis of metastasized MTC.
patient in the morning prior to any diagnostic procedure in our outpatient clinic at a routine appointment. Blood samples were immediately mixed with EDTA to prevent coagulation and cooled down to 4˚C. Nucleated cells were isolated using a Percoll gradient (Pharmacia, Uppsala, Sweden) at a density of 1.09 g/ml within 2 h after withdrawal of blood. Serum for calcitonin, CEA and thyroid hormone measurements was obtained using the supernatant after centrifugation. Total cellular RNA was extracted using RNeasy blood kit (Qiagen, Hilden, Germany) according to the suggestions of the manufacturer and RNA was resuspended in 50 µl RNase-free water. Optical transmission of the final RNA-preparation was determined three times at 260 nm using a Gene-Quant calculator (Pharmacia Biotech, Freiburg, Germany) and the RNA concentration was calculated.
Oligonucleotide primers and probes
Calcitonin primers were used as described elsewhere (Bracq et al, 1993) . CEA primers were custom designed according to the human CEA cDNA sequence reported by Barnett et al (Gene Bank accession number M29540). All primers were synthesized and purified by MWG-Biotech (Ebersberg, Germany). CT primers bind exon 3 and 4 respectively, generate a 291 bp fragment and span a genomic DNA sequence so that cDNA and contaminating genomic DNA amplification products can be distinguished by size. CEA primers bind exon 2 and 4 respectively and generate a 328 bp fragment. To assess the intactness of amplifiable RNA two intron-spanning glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) primers that generate a 300 bp fragment (Gene Bank accession number M33197) were used. The specificity of the primer sets for CT, CEA and glyceraldehyde-3-phosphate-dehydrogenase, respectively, was verified by basic local alignment search tool (BLAST) computer search (Altschul et al, 1990) . The sequences of these PCR primers are listed in Table 1 .
Reverse transcriptase-polymerase chain reaction
Approximately 1.5 µg of total RNA was reverse transcribed in a final volume of 20 µl containing 4 µl 5× buffer (250 mM TrisHCl pH 7.5, 375 mM KCl, 15 mM MgCl 2 , 50 mM DTT), 20 units recombinant RNase inhibitor (Promega, Madison, WI, USA), 0.5 mM dNTP, 2.5 µM oligo dT and 200 units RNAse H minus M-MLV reverse transcriptase (Promega). The following PCR was performed in a total volume of 50 µl containing 3 µl of the RT-solution, 5 µl 10× reaction buffer (200mM Tris-HCl pH 8.4, 500 mM KCl), 0.5 µM forward and reverse primer, 0.2 µM of each dNTP, 2.5 units Taq-DNA polymerase and 1.5 mM MgCl 2 (Life Technology, Paisley, Scotland) using a tube-controlled DNA thermal cycler (AGS-Hybaid, Heidelberg, Germany). For amplification of CEA cDNA, samples were subjected to 3 min of denaturation at 94˚C followed by 30 cycles of 45 s at 94˚C, 30 s at 55˚C and 1 min 30 s at 72˚C, followed by additional 10 min at 72˚C. For amplification of CT cDNA, samples were subjected to 3 min of denaturation at 94˚C followed by 10 cycles of 45 s at 94˚C, 30 sec at 65˚C decrescendo cycle-bycycle to 55˚C and 1 min at 72˚C, followed by 20 cycles of 45 s at 94˚C, 30 s at 55˚C and 1 min at 72˚C followed by additional 10 min at 72˚C. In each experiment water was used as a negative control.
Analysis of amplified CT/CEA cDNA 10 µl PCR product was mixed with 2 µl 6× loading dye (MBI Fermentas, Vilnius, Lithuania) and run for 60 min on an 1.5% agarose gel in TBE buffer (0.1 M Tris pH 8.4, 90 µM boric acid, 1 mM EDTA). The gel was stained with ethidium bromide and the bands corresponding to the amplified fragments were visualized on UV-table. Sequencing of amplified CT/CEA fragments was performed using a commercial sequencing service (SeqLab, Göttingen, Germany).
Calcitonin/carcinoembryonic antigen RT-PCR assay sensitivity
RT-PCR assay sensitivity was determined by mixing total RNA isolated from whole blood of a negative control patient (negative with CT and CEA RT-PCR) with total RNA isolated from TT cell line in serial dilutions of 1:2, 1:5 and 1:10 steps, respectively. RT-PCR was performed and analysed as described above. Assuming that one TT cell contains approximately 10 pg total RNA, the lower detection limit of the described RT-PCR assay was calculated as TT cells/ ml whole blood.
Statistics
Statistical comparisons were done using Sigma-Stat statistical software (Jandel Scientific, Erkrath, Germany). Contingency tables were used to assess the association between RT-PCR positivity rates and research subject category. Fisher exact test was used to compare the distributions in contingency tables that had 5 or less expected observations in one or more cells. P < 0.05 was considered significant.
RESULTS

Detection of CT and CEA transcripts by RT-PCR
After optimization of conditions for reverse transcription and polymerase chain reaction we were able to detect calcitonin as well as 
carcinoembryonic antigen transcripts as the expected 291/328 bp amplicons in total RNA extracted from TT-cell culture by agarose gel electrophoresis (Figure 1 ). PCR products were sequenced and their identity was consistent with human calcitonin/carcinoembryonic antigen cDNA sequence (Gene bank accession numbers see Table 1 ). PCR amplification using total RNA isolated from TT-cells without prior reverse transcription was performed as described above. PCR without RT was unsuccessful in amplifying the products predicted from the cDNA sequence.
Sensitivity of RT-PCR assay
RT-PCR assay sensitivity was determined using mixed aliquots of total RNA isolated from TT-cells and lymphocytes of a negative control patient. Assuming that one TT-cell contains 10 pg total RNA, we could detect the equivalent of 200 TT-cells/ml blood using calcitonin PCR and 50 TT-cells/ml blood using carcinoembryonic antigen PCR by agarose gel electrophoresis (Figure 2 ).
Evaluation of RT-PCR assay in patients and controls
We evaluated 11 patients with medullary thyroid cancer, 7 of them with known metastasis (local recurrence), and 32 control patients without clinical signs or a history of thyroid disease. RT-PCR on all blood samples was performed using primers for calcitonin and carcinoembryonic antigen, respectively. Synthesis of cDNA was achieved in all cases, as determined by successful amplification of GAPDH cDNA in each sample. Using primers for calcitonin, we detected calcitonin mRNA in peripheral blood of 0/11 patients with MTC and 0/32 controls. Using primers for CEA, we detected CEA-mRNA in peripheral blood of 8/11 (72.7%) patients with MTC and 11/32 (34.4%) controls (P = 0.038; Fisher-exact-test; Table 2 ). Figure 3 exemplarily shows a patient with sporadic medullary thyroid carcinoma and a nearly 10-year history of the disease. After multiple surgical interventions, tumour mass increased rapidly and the patient was no longer operable. Peripheral blood samples taken from this patient over a period of 6 months were always tested negative for calcitonin but positive for carcinoembryonic antigen mRNA. Calcitonin serum level was > 16 500 pg/ml (normal value < 20 pg/ml) and carcinoembryonic antigen serum level was 141 ng/ml (normal value < 4 ng/ml). Patient with sporadic medullary thyroid carcinoma and a nearly 10-year history of the disease. After multiple surgical interventions, tumour mass increased rapidly and the patient was no longer operable. Peripheral blood samples taken from this patient over a period of 6 months were always negative tested for calcitonin but positive for carcinoembryonic antigen mRNA. Calcitonin serum level was >16 500 pg/ml (normal value < 20 pg/ml) and carcinoembryonic antigen serum level was 141 ng/ml (normal value < 4 ng/ml)
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DISCUSSION
Diagnosis of local disease recurrence or metastasis in medullary thyroid carcinoma (MTC) remains to pose a diagnostic challenge in clinical practice. In this study, we evaluated whether detection of circulating calcitonin and CEA mRNA may add additional information to established studies for detection of recurrent disease. Molecular detection of tissue specific gene expression in peripheral blood is a new diagnostic approach and has been described as a tumour marker in different solid tumours (Johnson et al, 1995) . In some malignant diseases -for example prostate cancer -detection of circulating tumour cells could be shown to precede the detection of secondary disease by serum markers determined by immunoassays (Ghossein et al, 1995) . One study has been published, which has explored blood borne cytokeratin 20 mRNA as a potential tumour marker in thyroid cancer, especially MTC (Weber et al, 2000) . To date, calcitonin and carcinoembryonic antigen mRNA have only been described as diagnostic tools for preoperative diagnosis of MTC in leftover cells from fine needle aspiration biopsy (Takano et al, 1999; Bugalho et al, 2000) .
Using RT-PCR, calcitonin mRNA could neither be detected in peripheral blood of patients with MTC nor in controls in the present study, although serum levels of calcitonin (CT) were elevated in all patients with MTC and disease recurrence. Furthermore, multiple peripheral blood samples could be analysed for CT mRNA in a patient with known metastasis and massive tumour mass in the neck (Figure 3 ). Despite the fact that CT serum levels were highly increased in this patients, detection of circulating CT mRNA in this patient failed over a period of 6 months.
Although RT-PCR is a highly sensitive method of detect tumour and tissue-specific mRNA, for several reasons, detection of CTmRNA in peripheral blood may have failed.
First, RT-PCR assay-sensitivity may be to low to detect circulating CT-mRNA. We could determine assay-sensitivity to detect 200 CT-mRNA experssing cells/ml whole blood. This sensitivity is in the range of other comparable studies (Ditkoff, et al 1996; Weber et al, 2000) . From a technical point of view assy-sensitivity can be increased easily, but as we and others have described earlier, higher assay-sensitivities resulted in completely unspecific results (Tallini et al, 1998; Bojunga et al, 2000) . Other investigators were able to detect cytokeratin 20 mRNA -suspected as a tumour specific marker -in peripheral blood of three out of eight patients with MTC and concluded that CK20 RT-PCR assay is able to detect circulating tumour cells in peripheral blood of thyroid carcinoma patients (Weber et al, 2000) . However, the limitation of this study is that tissue specificity of the transcripts was not evaluated and as others have shown (Jung et al, 1999) , the detection of micrometastasis by cytokeratin 20 RT-PCR is limited due to stable background transcription in granulocytes. In addition, blood samples from only eight patients with MTC were studied. In view of these results, further studies are necessary to determine whether cytokeratin 20 may be a candidate for detection of circulating tumour cells in MTC as well.
Second, medullary thyroid carcinoma exhibits several biological peculiarities. Before metastasis in a distant site can develop, tumour cells must circulate in the peripheral blood or lymphatic channels. MTC typically forms metastasis in the local lymph nodes of the neck region and of the proximal mediastinum (Bergholm et al, 1989) . In patients with elevated basal calcitonin values during family screening programs, local lymph node involvement could be found in 50% of patients. Patients with clinically manifest tumours suffered from local metastases in 71% of cases (Wells et al, 1978) . Local lymph node involvement is the strongest predictor for disease survival in MTC: in the study of Woolner et al (Woolner et al, 1969) the 10-year survival rate of patients without lymph node involvement was not significantly different to a reference population (85%), whereas survival was reduced to 42% in patients with lymph node involvement. So the reason for the failure of detecting CT-mRNA expressing cells in our patients with MTC may be that tumour cells may only circulate in peripheral blood very late in the natural history of the disease. Furthermore, occurrence of negative peripheral blood samples in patients with metastatic disease has been noted in other tumour models, and intermittent release of tumour cells in the bloodstream may be one additional explanation (Ghossein and Rosai, 1996) .
Using primers specific for CEA, we could detect CEA mRNA significantly more often in patients with MTC (72,7%) than in controls (34,4%; P < 0.05). However, specificity and sensitivity are major concerns in RT-PCR systems for the detection of tumour cells in peripheral blood. Circulating CEA mRNA has widely been used in detection of metastasis in colo-rectal carcinoma and conflicting data have been published concerning false positive results for CEA mRNA in control patients: two groups using identical primer sequences did not find false positive cases in their studies and therefore reached assay specificity of 100% (Gerhard et al, 1994; Taniguchi et al, 2000) , whereas other groups reported false positive rates between 23% in bone marrow samples from healthy controls (Jonas et al, 1996) and 26% in peripheral blood samples from healthy controls (Zippelius et al, 1997) . Using our CEA RT-PCR assay with a sensitivity of 50 cells/ml blood, we were able to detect circulating CEA mRNA in 34% of healthy controls. The reason for this high percentage of RT-PCR positive controls remains unclear. One reason may be that non-specific low level expression of a variety of genes in different cell types, or illegitimate transcription, also occur in peripheral-blood leukocytes. Therefore, detection of CEA mRNA in peripheral blood might reflect detection of non-specific or illegitimate transcription in cell types of non-c-cell origin -e.g., lymphocytes or granulocytes -as it has been described earlier (Chelly et al, 1989) . Multiple peripheral blood samples could be analysed for CEA mRNA from the patient mentioned above (Figure 3) . CEA serum levels were also markedly increased in this patients and he was tested positive for circulating CEA mRNA several times over a period of 6 months.
Together, our results demonstrate that calcitonin mRNA does not seem to be a candidate for the detection of circulating tumour cells in MTC. However, in contrast to circulating calcitonin mRNA, our data suggest that the use of carcinoembryonic mRNA may provide a significant improvement in diagnosis of recurrent disease in MTC. Additional studies with quantitative assay format, larger groups of patients with long-term clinical follow up and establishment of cut-off values are necessary to further define the clinical value and diagnostic sensitivity and specificity of CEA mRNA RT-PCR assays in detecting disease recurrence in MTC.
